Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 18th 2024

The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.

Bicistronic CD19/CD22-Directed CAR T-Cell Therapy Is Safe, Elicits Durable Responses in Pediatric R/R B-ALL

December 7th 2024

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

November 25th 2024

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia

October 29th 2024

The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

October 16th 2024

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

Dr Armenian on Improving Outcomes and Reducing AEs in Pediatric Oncology

September 26th 2024

Saro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.

Dr Armenian on Challenges With Transitioning from Pediatric to Adult Cancer Care

September 25th 2024

Saro H. Armenian, DO, MPH, discusses the difficulties that patients face when transitioning from pediatric to adult cancer care, highlighting unmet needs.

LP-184 Earns 3 FDA Rare Pediatric Disease Designations Across Ultra-Rare Tumor Types

September 24th 2024

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

Non-Hispanic Black Children Experience Inferior Post-Relapse Survival Outcomes vs Whites With Nonmetastatic Osteosarcoma

September 19th 2024

R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, ethnicity, and survival outcomes in pediatric nonmetastatic osteosarcoma.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

September 4th 2024

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

FDA Grants Orphan Drug Designation to Opaganib for Neuroblastoma

August 27th 2024

Opaganib has received orphan drug designation from the FDA for use in patients with neuroblastoma.

INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma

August 23rd 2024

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Repotrectinib Adds to the Treatment Armamentarium for NTRK+ Advanced Solid Tumors

August 21st 2024

Luis E. Raez, MD, FACP, FCCP, FASCO, discusses the FDA approval of repotrectinib for NTRK-positive advanced solid tumors.

FDA Approves Vorasidenib for IDH1/2+ Grade 2 Astrocytoma or Oligodendroglioma

August 6th 2024

The FDA has approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

July 23rd 2024

The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.

Remestemcel-L BLA Is Resubmitted for Steroid-Refractory aGVHD

July 9th 2024

The BLA seeking approval for remestemcel-L for children with steroid-refractory acute graft-vs-host-disease has been resubmitted to the FDA.

Lutetium Lu 177 Dotatate Enters the Pediatric Treatment Paradigm for SSTR+ GEP-NETs

June 27th 2024

Daniel M. Halperin, MD, details the FDA approval of lutetium Lu 177 dotatate as well as safety and efficacy data in pediatric and adult patients treated with the agent.

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

May 29th 2024

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.